Merck's relebactam dubbed qualified infectious disease product

Merck revealed on 4 September its investigational beta-lactamase inhibitor relebactam (MK-7655) was dubbed a qualified infectious disease product (QIDP) by the FDA.

Merck revealed on 4 September its investigational beta-lactamase inhibitor relebactam (MK-7655) was dubbed a qualified infectious disease product (QIDP) by the FDA.

As a QIDP-designated medicine – a status the FDA has granted at least 52 times to 35 unique molecular entities...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anti-infective

More from Therapeutic Category